Related Experiment Video
Updated: Aug 9, 2026
07:06
Surgical Technique for the Implantation of a Biomimetic Artificial Intervertebral Disc in a Goat Animal Model
Published on: October 10, 2025
Biowaiver monographs for immediate release solid oral dosage forms: amitriptyline hydrochloride
R H Manzo1, M E Olivera, G L Amidon
1Pharmacy Department, Chemical Sciences Faculty, National University of Córdoba, Córdoba, Argentina.
Journal of Pharmaceutical Sciences
|March 25, 2006
Summary
A biowaiver for immediate-release amitriptyline hydrochloride tablets is recommended. This is possible if the drug is formulated with known excipients and meets dissolution standards, avoiding in vivo bioequivalence testing.
Area of Science:
- Pharmaceutical Sciences
- Drug Development
- Regulatory Science
Background:
- Amitriptyline hydrochloride is used for various therapeutic applications.
- Understanding its pharmacokinetic properties and potential excipient interactions is crucial for formulation.
- Previous bioequivalence (BE) and bioavailability (BA) data inform regulatory decisions.
Purpose of the Study:
- To review literature data for a biowaiver decision for amitriptyline hydrochloride IR solid oral dosage forms.
- To assess the suitability of waiving in vivo BE testing based on available scientific evidence.
Main Methods:
- Comprehensive literature review of amitriptyline hydrochloride properties.
- Analysis of pharmacokinetic data, solubility, and permeability.
- Evaluation of potential excipient interactions and reported BE/BA issues.
Main Results:
- Amitriptyline hydrochloride is identified as a highly permeable active pharmaceutical ingredient (API).
- Definitive Biopharmaceutics Classification System (BCS) classification was limited by incomplete solubility data.
- Existing data supports a biowaiver under specific formulation and dissolution conditions.
Conclusions:
- A biowaiver for immediate-release (IR) amitriptyline hydrochloride tablets is currently recommended.
- The waiver is contingent upon using established excipients from approved products.
- Meeting defined dissolution criteria is a mandatory requirement for the biowaiver approval.
Related Concept Videos
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:27Drug Delivery Systems: Different Types
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...